Abstract: Material characterized by that the material contains at least one biologically active saccharide which is covalently bound via at least one spacer to a crosslinked matrix.
Abstract:
wherein
when Y is
or heteroaryl;
A is —O(CH2)m, S, —NH(CH2)m, or (CH2)n where n is 0-3 and m is 0-2;
and R1 to R6 are as defined herein.
A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents, and/or one, two or more hypolipidemic agents.
Type:
Grant
Filed:
February 23, 2001
Date of Patent:
January 27, 2004
Assignee:
Bristol-Myers Squibb Company
Inventors:
William N. Washburn, Philip M. Sher, Gang Wu
Abstract: The invention relates to novel disaccharides of formula (I), wherein R1 is selected from the group consisting of hydrogen, linear or branched (C1-C4) alkyl, phenylalkyl with less than ten carbon atoms and —COCH3; R2 is selected from the group consisting of hydrogen, —COCH3 and SO3M; R3 is selected from the group consisting of hydrogen, linear or branched (C1-C4) alkyl, phenylalkyl with less than ten carbon atoms, —COCH3 and y —COPh, Ph being phenyl; G is selected from amongst —COOR4 and —COOM, R4 is selected from the group consisting of hydrogen, (C1-C2)-alkyl and arylalkyl with less than sixteen carbon atom; A is selected from the group consisting of hydrogen, —SO3H, —SO3M and —COCH3; B is selected from the group consisting of hydrogen, —SO3H, —SO3M and —COCH3, wherein either A or B are necessarily either —SO3H or —SO3M, M being a an organic or metallic cation.
Type:
Grant
Filed:
January 10, 2003
Date of Patent:
January 20, 2004
Assignee:
Bioiberica, S.A.
Inventors:
Francisco Javier Vila Pahi, Francesc Flores Salgado, Ramon Ruhi Roura, NarcĂs Arnau Pastor
Abstract: The present invention provides an anti-stilbene antibody. Preferably, the antibody is a monoclonal antibody. Exemplary and preferred such antibodies are designated herein as 19G2, 20F2, 21C6, 22B9, 25F8, 25E2, 23E4, 23G3, 23D3, 23C2, 25C10, 24B6, 21E2, 16H10 and 9E11. The present invention further provides hybridomas that produce and secrete anti-stilbene antibodies. An antibody of the present invention has particular utility in processes for identifying and/or locating target moieties appended to or incorporating antigenic stilbene. In one embodiment, therefore, the present invention further provides a method of detecting antigenic stilbene. The method includes the steps of exposing antigenic stilbene to an anti-stilbene antibody and detecting an anti-stilbene antibody-stilbene immunoconjugate. Such immunoconjugates can be detected using fluoroscopic procedures.
Type:
Application
Filed:
June 26, 2003
Publication date:
January 8, 2004
Inventors:
Peter Wirsching, Kim D Janda, Richard A. Lerner
Abstract: A method is described for treating hypercholesterolemic atherosclerosis or for reducing total cholesterol while raising high-density lipoportoein cholesterol. It involves administering to a patient a substantially pure complex derived from flaxseed and containing secoisolariciresinol diglucoside (SDG), cinnamic acid glucosides and hydroxymethyl glutaric acid.
Type:
Grant
Filed:
May 10, 2002
Date of Patent:
January 6, 2004
Assignee:
University of Saskatchewan Technologies Incorporated
Abstract: The invention concerns an alkaloid glycoside for use in medicine. In a preferred aspect, the alkaloid glycoside is used for the stimulation of a class I-restricted immune response and/or a class II-restricted immune response. In a preferred aspect, the alkaloid glycoside is tomatine.
Type:
Grant
Filed:
August 27, 1999
Date of Patent:
January 6, 2004
Assignees:
University of Southampton, Queen Mary and Westfield College
Inventors:
George Simon Attard, William John Woodroofe Morrow, Palasingam Rajananthanan
Abstract: The present invention relates to a process for effectively preparing L-ribose, which is recognized as being highly important in relation to the development of new antiviral medicines, from 1,4-lactone compound.
Type:
Grant
Filed:
August 17, 2001
Date of Patent:
December 30, 2003
Assignee:
Hanchem Co., Ltd.
Inventors:
Sang Jo Lee, Myung Joon Seo, Nak Cheol Jeong, Gun Cheol Kim, Hyun Woung Hong, Sul A Kim
Abstract: The present invention provides fluorescent nucleoside analogs which comprise a fluorescent cyclic compound joined to a carbon of a sugar molecule such as pentose, hexose, ribose or deoxyribose or analogs thereof in either an &agr; or &bgr; configuration. The subject compounds are useful as probes in the study of the structure and dynamics of nucleic acids and their complexes with proteins. In addition, the subject compounds are useful in any technique which uses labeled oligonucleotides for detection. Non-fluorescent spacer molecules in which a cyclohexane, cyclohexene, decalin, or benzene is joined to a carbon of a sugar moiety such as pentose, hexose, ribose or deoxyribose are also provided. Also provided are the 5′ dimethoxytrityl-3′-O-phosphoramidite derivatives, suitable for incorporation into oligonucleotides by automated synthesizers.
Abstract: An anticancer drug includes a compound represented by Formula (1):
where R101 represents an acyl moiety of a saturated higher fatty acid, and R102 represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.
Abstract: The current invention relates to the design, synthesis, and biochemical evaluation of chromogenic substrate compounds for sialidases of bacterial, viral, protozoa, and vertebrate (including human) origin. In particular, this invention provides a novel class of effective compounds as chromogenic substrates of these sialidases which yield chromogenic products after reactions catalyzed by sialidase take place. Also provided are methods of making these substrate compounds, methods of diagnosis and prognosis of sialidase related diseases using these substrate compounds.
Type:
Grant
Filed:
October 5, 1999
Date of Patent:
December 23, 2003
Assignees:
Ibbex, Inc., UAB Research Foundation
Inventors:
Stephen C. Johnson, Ming Lou, Shijia Yan
Abstract: The object of the present invention is a process for producing pure guarseed flour which produces a transparent and highly viscous solution when dissolved in water. Despite extensive purification, the process provides good yields of pure guarseed flour. The process comprises acid treatment of the initial material, washing the acid-treated split with water and/or neutralization with an aqueous alkaline solution, washing with water and dewatering using an aqueous alcohol solution. Transparent, highly viscous solutions of pure guarseed flour obtained by this process are primarily used in the food industry.
Abstract: This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.
Abstract: Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.
Type:
Application
Filed:
March 7, 2001
Publication date:
December 4, 2003
Inventors:
Scott Hultgren, Meta Kuehn, Zheng Xu, Derek Ogg, Mark Harris, Matti Lepisto, Charles Hal Jones, Jan Kihlberg
Abstract: The invention provides an immunopotentiating composition and to a composition accelerating the production of interferon-&ggr;, both comprising lactosuclose as an active ingredient. In particular, the invention provides such compositions in the form of a foodstuff. Oral administration or ingestion of the compositions enhances biophylaxis mechanism (immunological function) in the digestive tract, thus achieving significant treating and preventing effects on intestinal infections and like diseases.
Abstract: The present invention provides a method of synthesizing an allyl pentasaccharide having the structure:
as well as related oligosaccharide ceramides and other glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer cells in an adjuvant therapy therefor, and in a method for preventing recurrence of epithelial cancer.
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
November 11, 2003
Assignees:
Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City New
York
Inventors:
Samuel J. Danishefsky, Victor Behar, Kenneth O. Lloyd
Abstract: The present invention relates to dehydrated dextrose monohydrate having a specific surface area of from 0.20 m2/g to 0.50 m2/g and is reducing the reaction time for preparing chemical compounds selected from the group consisting of alkyl glucoside, alkenyl glucoside, alkyl polyglucosides and alkenyl polyglucosides in a heterogeneous mixture with an alcohol. The present invention further discloses a process for preparing dehydrated dextrose monohydrate and a process for preparing chemical compounds selected from the group consisting of alkyl glucoside, alkenyl glucoside, alkyl polyglucosides and alkenyl polyglucosides by applying dehydrated dextrose monohydrate.
Type:
Grant
Filed:
September 13, 2001
Date of Patent:
November 11, 2003
Assignee:
Cerestar Holding B.V.
Inventors:
Reiner Höpcke, Richard James Tippett, Christof Küsters
Abstract: A hair treatment composition containing: (a) an esterquat; (b) an alkyl and/or alkenyl oligoglycoside; (c) a partial glyceride; and (d) a fatty alcohol ethoxylate.
Abstract: The present invention provides a fluorescent substance which is represented by a formula: A-B-C
wherein
A is a residue of natural or synthetic nucleotide, oligonucleotide, polynucleotide, or derivative thereof, and binds to B at a base moiety in said residue, or A is a residue of avidin or streptavidin;
B is a divalent linking group or a single bond; and
C is a monovalent group derived from a general formula (I) and binds to B at a reactive group present in R1 or R2:
wherein R1 and R2 each independently represent an alkyl group that may be substituted with a reactive group capable of covalently bonding to A-B-; R3, R4, R5, and R6 each independently represent an alkyl group, and R3 and R4, and/or R5 and R6 may bind to each other to form a saturated carbon-ring together with a carbon atom(s) to which they bind; V1, V2, V3, V4, V5, V6, V7, V8, V9 and V10 each independently represent a hydrogen atom or a monovalent substituent, and two adjacent groups thereof may bind to form a ring; L1, L2,
Abstract: A synthesis of [2.2.1]bicyclo nucleosides which is shorter and provides higher overall yields proceeds via the key intermediate of the general formula III, wherein R4 and R5 are, for instance, sulfonates and R7 is, for instance, a halogen or an acetate. From compounds of the general formula II, such as 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-&agr;-D-ribofuranose, intermediates of the general formula III are suitable for coupling with silylated nucleobases. Upon one-pot base-induced ring-closure and desulfonation of the formed [2.2.1]bicyclo nucleoside, a short route to each the LNA (Locked Nucleic Acid) derivatives of adenosine, cytosine, uridine, thymidine and guanidine is demonstrated. The use of the 5′-sulfonated ring-closed intermediate also allows for synthesis of 5′-amino- and thio-LNAs.
Type:
Grant
Filed:
March 24, 2000
Date of Patent:
October 28, 2003
Assignee:
Exiqon A/S
Inventors:
Alexei Kochkine, Jef Fensholdt, Henrik M. Pfundheller
Abstract: The subject invention provides compounds useful as fluorogenic substrates. Upon hydrolysis of a hydrolyzable group, a halo-pyrene substituted molecule is developed which is highly fluorescent, water soluble and exhibits several desirable characteristics, including a large Stokers' shift.
Abstract: The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine n a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also a method of producing the chemically modified mutant protein is provided. The present invention also relates to a glycosylated methanethiosulfonate. Another aspect of the present invention is a method of modifying the functional characteristics of a protein including providing a protein and reacting the protein with a glycosylated methanethiosulfonate reagent under conditions effective to produce a glycoprotein with altered functional characteristics as compared to the protein. In addition, the present invention relates to methods of determining the structure-function relationships of chemically modified mutant proteins.
Type:
Grant
Filed:
April 2, 2001
Date of Patent:
September 30, 2003
Assignee:
Genencor International, Inc.
Inventors:
Benjamin G. Davis, John Bryan Jones, Richard R. Bott
Abstract: The invention relates to a series of polyglycoside derivatives that contain water-soluble groups introduced into the molecule by reaction with the hydroxyl groups present in the starting polyglycoside molecule, with the chloro material. The preferred products have more than one water-soluble group per molecule and are made with mild reagents to avoid discoloration and mal odor. The most preferred products have between 2 and 3 functional groups per molecule.
Type:
Grant
Filed:
October 1, 2002
Date of Patent:
September 30, 2003
Assignee:
Colonial Chemical INC
Inventors:
Anthony J. O'Lenick, Jr., Kevin A. O'Lenick
Abstract: One aspect of the present invention relates to optionally substituted halogenated benzyl halides and the like. These compounds are useful as halogenated benzyl ether-based protecting groups for a variety of functional groups. Another aspect of the present invention relates to use of said protecting groups in an orthogonal protecting group strategy for the synthesis of complex molecules that comprise a number of suitable functional groups. Another aspect of the present invention relates to saccharides bearing various arrays of protecting groups of the present invention. Another aspect of the present invention relates to a method of synthesizing an oligosaccharide or glycoconjugate, comprising the steps of: using a saccharide bearing at least one protecting group of the present invention to glycosylate a second molecule to give a product comprising said saccharide; and removing a protecting group of the present invention from said product.
Type:
Application
Filed:
May 15, 2002
Publication date:
September 25, 2003
Inventors:
Stephen L. Buchwald, Obadiah J. Plante, Peter H. Seeberger
Abstract: Compounds according to formula I:
T1—L—T2 (I),
wherein T1 is a taxoid group, preferably of Formula II:
wherein R1 is C6H5; R2 is O; L is a linking group; and T2 is a substituent selected from the group consisting of epipodophyllotoxin, amsacrine, ellipticine, anthracycline antibiotic, mitoxantrone, and colchicine groups, and pharmaceutically acceptable salts thereof, are provided herein. The compounds are useful in, among other things, treating tumors or cancer in subjects in need thereof, inducing cellular differentiation, and inhibiting cellular mitosis.
Type:
Grant
Filed:
September 25, 2000
Date of Patent:
September 23, 2003
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Kuo-Hsiung Lee, Qian Shi, Kenneth F. Bastow, Hui-Kang Wang
Abstract: Esterified polysaccharides and the process of making such products are disclosed. The process can be enzymatic where an enzyme is used as a catalyst for the reaction. The process can also be chemical where no enzyme is used. Novel Products are obtained through lipase-catalyzed &bgr;-lactone ring opening alcoholysis of ketene dimers and the process of making such compositions containing products.
Abstract: A &bgr;-D-glucofuranose compound which is 1,2,3,5,6-penta-O-propanoyl-&bgr;-D-glucofuranose, preferably in crystalline form, is prepared from D-glucose. The compound is prepared by reacting D-glucose with boric acid, or an equivalent thereof, followed by treatment with a propanoylating reagent, preferably propanoic anhydride. The compound is useful for the preparation of other compounds, such as glucofuranosides.
Type:
Grant
Filed:
September 19, 2002
Date of Patent:
September 16, 2003
Assignee:
Industrial Research Limited
Inventors:
Richard Hubert Furneaux, Phillip Martin Rendle, Ian Michael Sims
Abstract: Modified polysaccharides (such as starches, gums, chitosans, celluloses, alginates, sugars, etc.), which are commonly used in the paper industry as strengthening agents, surface sizes, coating binders, emulsifiers and adhesives, can be combined into a single molecule with amphiphilic hydrocarbons (e.g. surface active agents) which are commonly utilized in the paper industry to control absorbency, improve softness, enhance surface feel and function as dispersants. The resulting molecule is a modified polysaccharide having surface active moieties which can provide several potential benefits, depending on the specific combination employed, including: (a) strength aids that do not impart stiffness; (b) softeners that do not reduce strength; (c) wet strength with improved wet/dry strength ratio; (d) debonders with reduced linting and sloughing; (e) strength aids with controlled absorbency; and (f) surface sizing agents with improved tactile properties.
Type:
Grant
Filed:
September 5, 2002
Date of Patent:
September 16, 2003
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Thomas Gerard Shannon, Daniel Arthur Clarahan, Mike Thomas Goulet, Wen Zyo Schroeder
Abstract: {circle around (1)} Compounds of the following general formula (1) having a glucuronic acid derivative and a glucosamine derivative in the structure thereof, pharmacologically acceptable salts and solvates of the compounds, or solvates of the salts, {circle around (2)} a method for producing the compounds {circle around (1)}, {circle around (3)} a pharmaceutical composition containing the compounds {circle around (1)}, {circle around (4)} polymers having at least one of the compounds {circle around (1)} as a side chain structure, {circle around (5)} a coating agent containing the compound {circle around (1)} or the polymer as one of active ingredients, and {circle around (6)} molded products, artificial organs, medical devices, and equipment for cell culture, which have been produced using the polymer {circle around (4)} and/or the coating agent {circle around (5)}.
Abstract: Carboxyl-containing fructans such as carboxymethylinulin can be successfully used to prevent deposition of scale composed of, for example, calcium, barium and strontium salts of sulphuric acid and carbonic acid in oil extraction. In the oil extraction method, 0.5-200 ppm of a carboxyl-containing fructan that contains 0.3-3 carboxyl groups per mono-saccharide unit is incorporated in the process water, in the process equipment or in the oil-containing formation.
Abstract: Derivatives of sphingolipids of the formula:
are provided wherein the substituents are as defined in the specification and wherein there is at least one R2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof.
Type:
Grant
Filed:
February 12, 1999
Date of Patent:
August 26, 2003
Assignee:
Emory University
Inventors:
Dennis C. Liotta, Alfred H. Merrill, Jr., Thomas E. Keane, Kapil N. Bhalla, Eva M Schmelz
Abstract:
Medicinal compositions for treating or preventing diabetes, rheumatoid, diseases wherein inflammation should be inhibited, diseases wherein &agr;-glycosidase should be inhibited, diseases wherein the synthesis of prostaglandin should be inhibited, diseases wherein endotoxin shock should be inhibited, diseases wherein the production of interleukin should be inhibited, diseases wherein the production of heme oxygenase should be induced, and diseases wherein the production of tumor necrosis factor or carcinogenesis should be inhibited, which contain as the active ingredient at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula (I), its aldehyde, its hydrate and 2-O-methylated derivatives and 2-O-sulfated derivatives thereof.
Abstract: A microorganism which belongs to the genus Gliocladium and has the ability to produce stereoisomers KF-1040T4A and KF-1040T4B which are compounds represented by the following formula [I],
and stereoisomers KF-1040T5A and KF-1040T5B which are compounds represented by the following formula [II],
is cultivated in a culture medium to accumulate KF-1040T4A and/or KF-1040T4B and/or KF-1040T5A and/or KF-1040T5B in the culture medium, and the substance KF-1040T4A and/or KF-1040T4B and/or KF-1040T5A and/or KF-1040T5B are harvested from the culture medium. The obtained substances are useful for the prevention and treatment of the diseases relating to arteriosclerosis, obesity, thrombosis, inflammations and immunofunctional disorders.
Abstract: The invention relates to an improved process for the synthesis and application of sugar esters, that are useful as effective, environmentally-safe pesticides for the control of soft-bodied arthropod pests.
Type:
Grant
Filed:
July 11, 1994
Date of Patent:
August 19, 2003
Assignee:
The United States of America as represented by the Secretary
of Agriculture
Abstract: Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
August 19, 2003
Assignees:
Alberta Research Council, Integris Baptist Medical Center, Inc.
Inventors:
A. Heather Good, David K.C. Cooper, Andrew J. Malcolm
Abstract: The invention relates to curcumin derivatives with improved water solubility compared to curcumin, which are characterized in that the curcumin part is linked to a monosaccharide, oligosaccharide or polysaccharide, and to medicaments containing these derivatives. The curcumin derivatives according to the invention are particularly suitable to prevent and treat cancer, chronic-inflammatory diseases and diseases associated with a retrovirus infection.
Type:
Application
Filed:
April 8, 2003
Publication date:
August 14, 2003
Inventors:
Manfred Hergenhahn, Barbara Bertram, Manfred Wiessler, Bernda L Sorg
Abstract: The invention relates to an improved process for the synthesis and application of sugar esters, that are useful as effective, environmentally-safe pesticides for the control of soft-bodied arthropod pests.
Type:
Grant
Filed:
April 7, 1997
Date of Patent:
August 12, 2003
Assignee:
The United States of America as represented by the Secretary
of Agriculture
Abstract: The invention provides a process to prepare a complex of adsorption charcoal-GM1 stable at different pH values. This process is based on the suspension method, the formulation example being presented. An analytical method to determine non derivatized GM1 in aqueous solutions using the high efficiency liquid chromatography technique is also object of the present invention.
Type:
Grant
Filed:
June 5, 2002
Date of Patent:
August 5, 2003
Assignee:
TRB Pharma Industria Quimica e Farmaceutica Ltda
Inventors:
Silvia Storpirtis, Pedro Gonçalves De Oliveira
Abstract: The present invention relates to the use of self-assembled monolayers with mixtures of conductive oligomers and insulators to detect target analytes.
Abstract: The present invention relates to novel caloporoside derivatives and method of their use. The caloporoside derivatives may be formed by fermentation of microorganisms, such as Gloeoporus dichrous (Fr.: Fr.) Bres. ST001714 (DSM 13784). The invention also relates to use to a process for preparing caloporoside derivatives, drugs comprising such compounds, and methods of their use. The invention further relates to the microorganism Gloeoporus dichrous Bres. ST001714 (DSM 13784).
Type:
Grant
Filed:
March 8, 2002
Date of Patent:
July 22, 2003
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Claudia Eder, Michael Kurz, Mark Brönstrup, Luigi Toti
Abstract: The invention relates to an adhesive composition comprising a derivative of a starch, which comprises at least 95 wt. % of amylopectin, based on dry substance of the starch, wherein the derivative is obtainable by cross-linking, etherification, esterification or a combination thereof, of the starch. The invention further relates to a process for preparing the adhesive composition and to the use thereof for adhering wallpaper or billposter to a substrate.
Type:
Grant
Filed:
March 12, 2001
Date of Patent:
July 22, 2003
Assignee:
Cooperatieve Verkoop-en Productievereniging van Aardappelmeel
en Derivaten AVEBE B.A.
Inventors:
Ronald Peter W. Kesselmans, Ido Pieter Bleeker, Willem Kamminga
Abstract: Camptothecin derivatives of camptothecin of formula (I):
wherein the groups R1, R2 and R3 are as defined in the description are disclosed.
The compounds of formula (I) are endowed with antitumor activity and show a good therapeutic index.
Processes for the preparation of the compounds of formula (I) and their use in the preparation of medicaments useful in the treatment of tumors, viral infections and antiplasmodium falciparum are also disclosed.
Abstract: This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid and the methods of treating such pathologies as listed above.
Type:
Grant
Filed:
March 25, 1999
Date of Patent:
July 8, 2003
Assignee:
Ranbaxy Laboratories Limited
Inventors:
Sudershan K Arora, Nawal Kishore, Jang Bahadur Gupta, Vishwas D Joshi
Abstract: Sulfated fucogalactan or its salt useful as a reagent for sugar chain engineering or an HGF-production inducer; a degraded product or its salt obtained by treating the sulfated fucogalactan with a sulfated fucogalactan digesting enzyme; the sulfated fucogalactan digesting enzyme useful in sugar chain engineering; a process for producing the degraded product by treating sulfated fucogalactan or its salt with the above enzyme; and a process for producing the sulfated fucogalactan digesting enzyme.
Abstract: The present invention relates to a method for controlling the quality of oligomer arrays, which is characterized in that a phosphate unit is fused to certain array positions, said phosphate unit being linked to a signal-generating reporter group, the degree of oligomer synthesis is determined using the signal of the reporter group, and the reporter group is then split off again.
Abstract: The present invention provides preparations for efficaciously administering ginsenoside Rb1 or its salt useful as cytoprotective agents. More particularly, the present invention provides pharmaceutical compositions comprising ginsenoside Rb1 or its salt for inhibiting apoptosis or apoptosis-like cell death or pharmaceutical compositions comprising ginsenoside Rb1 or its salt for promoting the expression of a cell death-inhibitory gene product Bcl-xL. Further, the present invention provides preparations for intravenous administration comprising ginsenoside Rb1 or its salt. The above pharmaceutical compositions contain ginsenoside Rb1 or its salt at low extracellular concentrations in lesion, preferably at 1 ng/ml or less and still preferably at 1 to 100 fg/ml. These compositions promote the expression of the cell death-inhibitory gene product Bcl-xL and inhibit apoptosis or apoptosis-like cell death.
Type:
Grant
Filed:
June 22, 2001
Date of Patent:
June 17, 2003
Assignee:
Japan Science and Technology Corporation
Inventors:
Masahiro Sakanaka, Junya Tanaka, Kohji Sato
Abstract: Disclosed is a process for producing a high &agr;G-AA content product, which comprises the steps of: contacting a solution as a material solution, containing &agr;G-AA, L-ascorbic acid, and a saccharide(s), with an anion exchange resin packed in a column to adsorb the &agr;G-AA and L-ascorbic acid on the anion exchanger; washing the anion exchanger with water to remove the saccharide(s) therefrom; feeding to the column an aqueous solution, as an eluent, of an acid and/or a salt with a concentration of less than 0.5 N to fractionate a fraction rich in 2-O-&agr;-D-glucopyranosyl-L-ascorbic acid and a fraction rich in L-ascorbic acid; and collecting the former fraction.
Abstract: The invention is directed to synthetic receptor(s) which comprises a polyfunctional organic template covalently linked to two or more oligomers which may independently be the same or different and may independently be straight chain, cyclic or branched. The template may be linked to an identifier which uniquely defines the synthetic receptor. The identifier is a stable chemical molecule or a plurality of stable chemical molecules distinguishable and detectable to picomolar levels or may be an oligonucleotide. In a preferred embodiment, the template is covalently linked to a solid support which is linked to an identifier. In addition, the invention includes methods of preparing synthetic receptors and synthetic receptor libraries. The synthetic library may be linked with identifiers such that the library comprises a plurality of different synthetic receptor members.
Abstract: This invention provides lipids having: 1) a glycerol backbone; 2) a hydrocarbon chain, preferably saturated and containing 16 or 18 carbon atoms, attached to C-1 of the backbone by an ether linkage, 3) a methyl group attached to C-2 of the backbone, preferably by an ether linkage; and, 4) a sugar attached to C-3 of the glycerol backbone in either the alpha or beta anomeric configuration, the sugar being altered by modification of, or substitution for, one or more of its hydroxyl groups. Also provided herein are ether-lipid-containing compositions, as well as methods of administering such compositions to animals, for example, those afflicted with cancers, as well as various other diseases and disorders.
Type:
Grant
Filed:
August 23, 2000
Date of Patent:
June 3, 2003
Assignees:
The Liposome Company, Inc., The Research Foundation of the City University of New
York
Inventors:
Robert Bittman, Ravi K. Erukulla, Andrew C. Peters, Eric G. Mayhew
Abstract: Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such protein targets to inhibit nucleic acid metabolism. In addition, screening assays for identifying compounds that inhibit nucleic acid-dependent ATPase activity, including, but not limited to, DNA-dependent ATPase A, are disclosed. Such compounds are useful in the treatment of diseases, including but not limited to cancer and infectious disease, through disruption of nucleic acid metabolism and induction of apoptosis. Moreover, methods for prevention and treatment of diseases including, but not limited to cancer and infectious disease are disclosed.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
June 3, 2003
Assignee:
University of Virginia Patent Foundation